KSKaijia Shi

Kaijia Shi

*This is an algorithmically generated author record based on publicly available information.

Kaijia Shi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Jie

    Hainan Provincial Key Laboratory for Tropical Cardiovascular Diseases Research & Institute of Cardiovascular Diseases, Hainan Medical University, Haikou, China

    4 shared publications
  • Zhihua Shen

    Department of Pathophysiology, School of Basic Medicine Sciences, Guangdong Medical University, Zhanjiang 524023, China

    4 shared publications
  • Junli Guo

    Hainan Provincial Key Laboratory for Tropical Cardiovascular Diseases Research & Institute of Cardiovascular Diseases, Hainan Medical University, Haikou, China

    3 shared publications
  • Xu Chen

    Department of Intensive Care Unit, Yuhuangding Hospital, Yantai, China

    3 shared publications
  • Jianmin Qiu

    Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory for Tropical Cardiovascular Diseases Research of Hainan Province, School of Public Health, Hainan Medical University, Haikou, China

    2 shared publications
  • Jinxuan Chai

    Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory for Tropical Cardiovascular Diseases Research of Hainan Province, School of Public Health, Hainan Medical University, Haikou, China

    2 shared publications

Latest Publications

  • Open Access

    Phenotypic Age Acceleration as a Mediator in Thyroid Hormone–Related Cardiovascular Risk Among the Elderly

    by Minmin Wen, Yanjun Hou, Kaijia Shi, Jiaxin Zuo, Cheng Zhang, Shuya Zhang, Zhihua Shen, Wei Jie

    Background: The association between thyroid hormones and cardiovascular disease (CVD) has been widely examined; however, the role of biological aging in this relationship remains unclear. This study systematically investigates the mediating role of phenotypic age acceleration (PhenoAgeAccel) in the relationship between thyroid hormones and CVD. Methods: The data were sourced from the 2007–2010 cycles of the National Health and Nutrition Examination Survey (NHANES). Analyses included logistic regression, linear regression, restricted cubic splines, subgroup analyses, and mediation analysis to assess the role of PhenoAgeAccel. Results: Among participants aged ≥ 60 years, elevated free triiodothyronine (FT3) concentrations were linked to a reduced risk of CVD (adjusted odds ratio [aOR] = 0.483; 95% CI: 0.273–0.856; p = 0.013). Similarly, total triiodothyronine (TT3) levels were associated with a decreased CVD risk in those aged 60 and above (aOR = 0.988; 95% CI: 0.980–0.995; p = 0.013). Mediation analysis showed that PhenoAgeAccel mediated 21.13% of the FT3–CVD association and 23.41% of the TT3–CVD association in older adults. Conclusion: This study identifies an age‐dependent relationship between FT3, TT3, and CVD and reveals that PhenoAgeAccel partially mediates this association. These findings suggest that interventions targeting thyroid function and biological aging may offer novel strategies for CVD prevention and management in older populations.

  • Open Access

    Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis

    by Kaijia Shi, Xu Chen, Yangyang Zhao, Peihu Li, Jinxuan Chai, Jianmin Qiu, Zhihua Shen, Junli Guo, Wei Jie

    Nonischemic cardiomyopathy (NISCM) is a clinical challenge with limited therapeutic targets. This study aims to identify promising drug targets for NISCM. We utilized cis-pQTLs from the deCODE study, which includes data from 35,559 Icelanders, and SNPs from the FinnGen study, which includes data from 1,754 NISCM cases and 340,815 controls of Finnish ancestry. Mendelian randomization (MR) analysis was performed to estimate the causal relationship between circulating plasma protein levels and NISCM risk. Proteins with significant associations underwent false discovery rate (FDR) correction, followed by Bayesian colocalization analysis. The expression of top two proteins, LILRA5 and NELL1, was further analyzed using various NISCM datasets. Descriptions from the Human Protein Atlas (HPA) validated protein expression. The impact of environmental exposures on LILRA5 was assessed using the Comparative Toxicogenomics Database (CTD), and molecular docking identified the potential small molecule interactions. MR analysis identified 255 circulating plasma proteins associated with NISCM, with 16 remaining significant after FDR correction. Bayesian colocalization analysis identified LILRA5 and NELL1 as significant, with PP.H4 > 0.8. LILRA5 has a protective effect (OR = 0.758, 95% CI, 0.670–0.857) while NELL1 displays the risk effect (OR = 1.290, 95% CI, 1.199–1.387) in NISCM. Decreased LILRA5 expression was found in NISCM such as diabetic, hypertrophic, dilated, and inflammatory cardiomyopathy, while NELL1 expression increased in hypertrophic cardiomyopathy. HPA data indicated high LILRA5 expression in neutrophils, macrophages and endothelial cells within normal heart and limited NELL1 expression. Immune infiltration analysis revealed decreased neutrophil in diabetic cardiomyopathy. CTD analysis identified several small molecules that affect LILRA5 mRNA expression. Among these, Estradiol, Estradiol-3-benzoate, Gadodiamide, Topotecan, and Testosterone were found to stably bind to the LILRA5 protein at the conserved VAL-15 or THR-133 residues in the Ig-like C2 domain. Based on European Ancestry Cohort, this study reveals that LILRA5 and NELL1 are potential therapeutic targets for NISCM, with LILRA5 showing particularly promising prospects in diabetic cardiomyopathy. Several small molecules interact with LILRA5, implying potential clinical implication.


  • Open Access

    Causal association of polyunsaturated fatty acids with biliary tract diseases: A Mendelian randomization study

    by Xu Chen, Kaijia Shi, Yi Zhang, Yuqi Song, Xueyuan Wang, Xinghan Tian


  • Open Access

    Diabetes Advances Cardiomyocyte Senescence through miR-103a-3p/Rnd3/STAT3 Signaling

    by Linxu Wu, Xinglin Zhu, Cai Luo, Yan Chen, Yin Liu, Yangyang Zhao, Shanshan Pan, Kaijia Shi, Jingci Xing, Xuebin Lin, et al.

    BACKGROUND: Rnd3, a small Rho-GTPase, is involved in various cardiovascular diseases, but its role in diabetes-induced cardiomyocyte senescence is unclear. This study aims to investigate the role of Rnd3 in cardiomyocyte senescence in diabetes cardiomyopathy (DCM). METHODS: Rnd3 expression was assessed in human tissue using qPCR, and its correlation with clinical parameters was analyzed. Rnd3 and Senescence-associated secretory phenotype (SASP)-related marker expression was determined in heart tissue from juvenile/mature mice and streptozotocin-induced diabetic Sprague–Dawley rats. H9C2 and AC16 cardiomyocytes were exposed to high glucose ([HG] =35 mmol/L D-glucose), and Rnd3 and SASP-related marker expression was examined. Rnd3 expression in H9C2 cells was disrupted using CRISPR/Cas9 technology, and cellular senescence of HG-treated H9C2 cells was evaluated. MicroRNA sequencing was conducted on AC16 cells to identify differentially expressed microRNAs regulated by HG. Among these microRNAs, miR-103a-3p was selected for further investigation in a clinical diabetes cohort and to examine its binding to Rnd3 3′UTR and its effect on cell senescence. Finally, the role of interaction of Rnd3 and STAT3 in cardiomyocyte senescence was investigated. RESULTS: Rnd3 mRNA levels were reduced in peripheral blood mononuclear cells in diabetic patients, which was negatively correlated to patients age but positively correlated to cardiac function. Older mice exhibited compromised cardiac function, increased SA-β-gal-positive cells, and SASP marker levels versus younger mice. HG stimulation inhibited Rnd3 expression but enhanced cellular senescence. Rnd3 knockout resulted in greater cellular senescence on HG-insulted cardiomyocytes. miR-103a-3p was identified as a key HG-regulated microRNA that binds to Rnd3 3′UTR. AAV9 carrying miR-103a-3p sponges and Rnd3 -overexpressing plasmids mitigated cellular senescence in diabetic rats. Interestingly, miR-103a-3p levels positively correlated with blood glucose concentrations. HG stimulation amplified phosphorylated STAT3(Tyr705) in H9C2 cells, which was intensified by Rnd3 knockout. Rnd3 binds with STAT3 in cytoplasm and promote proteasome-induced ubiquitination of STAT3. S3I-201 mitigated HG-activated STAT3 and cardiomyocyte senescence. CONCLUSION: Diabetes causes cardiomyocyte senescence through miR-103a-3p/Rnd3/STAT3 signaling, suggesting a potential treatment strategy for DCM.